CION Ameerpet
If your ovarian cancer has come back, one date shapes the next conversation more than any other — the day you had your last dose of platinum-based chemotherapy. The gap between that day and the day the cancer was found again is the platinum-free interval, and it is the first thing your oncologist works out. It guides which treatment comes next. It is not a countdown, and it is not a prognosis.
It is one subtraction. Take the date of your last dose of platinum-based chemotherapy. Take the date the cancer was shown to have come back or started growing again. The gap between them is the platinum-free interval, usually shortened to PFI. Nothing else goes into it — not your stage, not your age, not how well you feel today.
People searching platinum free interval ovarian cancer are usually in one of two places. Either they have just been told the disease is back and heard the words platinum-sensitive or platinum-resistant used about them, or they are counting months on a calendar and trying to work out which side of a line they will land on. Both deserve a straight explanation rather than a shrug.
The interval matters for one reason: across decades of trials it has been the best single predictor of whether platinum-based chemotherapy will work a second time. The longer the gap, the more likely another platinum-based course is to shrink the disease. That is what the number is for. It chooses a class of treatment. It does not measure how long anyone has.
The last dose of platinum-based chemotherapy you actually received — not the day of your surgery, not the day you were diagnosed, and not the last day of a maintenance tablet. If your first-line chemotherapy finished in March, the clock started in March.
The day relapse was documented — usually a scan showing disease again, sometimes a confirmed CA-125 rise with symptoms. If your team dated the relapse to the scan rather than to when you first felt unwell, that is why the number may look shorter than it feels.
Choosing what comes next. A long interval makes another platinum-based course sensible; a short one points to a different class of drug. The wider picture is set out in what happens when ovarian cancer comes back.
For twenty-five years relapse was sorted into two boxes — platinum-sensitive or platinum-resistant — with six months as the dividing line. At the 5th Ovarian Cancer Consensus Conference (Gynecologic Cancer InterGroup, Tokyo, 2015) that binary was formally set aside. The conference recommended describing relapse by the treatment-free interval, measured separately from platinum, from all chemotherapy and from non-platinum treatment, precisely because the six-month cut-off was never a biological switch. It was a convenient line drawn through a continuum, adopted so that trials could be designed and compared. Guidelines still use the old words as shorthand, but not as a diagnosis. Source: Wilson MK et al., 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup, Annals of Oncology (2017); NCCN Ovarian Cancer guidelines.
These bands come from trial data and they are still how most oncologists speak. Read them as a gradient rather than as four separate diseases — the difference between month five and month seven is a line on a page, not a change in the cancer.
| Time since the last platinum dose | The term you will hear | What it usually means for the next plan |
|---|---|---|
| Progression during treatment, or within about four weeks of the last dose | Platinum-refractory | Platinum is not repeated. The conversation turns to a different class of chemotherapy, to controlling symptoms well, and to whether a clinical trial fits. |
| Under 6 months | Platinum-resistant | Usually a non-platinum, single-agent chemotherapy, sometimes with anti-angiogenic therapy. Quality of life carries as much weight as shrinking the tumour. The routes are set out in platinum-resistant ovarian cancer — the options. |
| 6 to 12 months | Partially platinum-sensitive | The genuinely grey zone. Platinum may be re-used, often in combination, or deliberately held back. Symptoms, earlier side effects, and BRCA and HRD status often decide it. |
| Over 12 months | Platinum-sensitive | Platinum-based combination chemotherapy is usually offered again, with a real chance of another good response, and maintenance therapy considered once that response is achieved. |
| Over 24 months | Platinum-sensitive, long interval | The same route, with the best odds of response — and the situation in which surgery at relapse is most likely to be discussed, with a specialist partner centre. |
*These are conventions for choosing treatment, not diagnostic categories. Two women with an eight-month interval can reasonably be offered two different plans, and both be right.
The interval answers one question well and several questions badly. Here is where it carries real weight, and where people read far more into it than it can hold.
This is the interval's real job. A long gap means the disease responded well and stayed away, and that pattern predicts another response to platinum-based combination chemotherapy. A short gap means the cancer regrew while platinum was still recently on board, so giving the same class again is unlikely to achieve much while still costing you the side effects.
Everything else follows from that single decision: whether a combination or a single agent is used, whether anti-angiogenic therapy is added, and what maintenance therapy is considered afterwards. Your oncologist is not sorting you into a category for its own sake. They are choosing the class of drug most likely to work.
A short interval is frequently heard as “nothing will work”. That is not what it means. It means platinum is unlikely to work well again, so a different class is chosen — and other classes do produce responses, control symptoms and buy good time. The aim shifts towards control and comfort rather than cure, but the aim is still to treat.
The other reason the interval cannot decide this is that people are not their scans. Fitness, kidney and marrow function, nerve damage left over from earlier chemotherapy, and what you want from the next few months all belong in the decision. A number on a calendar cannot weigh any of those.
If you took PARP-inhibitor-class maintenance therapy for a year after chemotherapy and relapsed shortly after stopping, your platinum-free interval is long — well over twelve months — while your treatment-free interval is only weeks. Those two numbers tell different stories, and quoting the wrong one leads to the wrong plan.
This is exactly why the consensus conference moved towards the treatment-free interval. If you have had maintenance therapy, ask which interval is being used about you, and make sure both dates are written in your notes: the last platinum dose, and the last dose of anything at all.
The interval says nothing about tumour biology on its own. A BRCA pathogenic variant, or homologous recombination deficiency in the tumour, tends to travel with better platinum responses and longer intervals — and, separately, changes whether PARP-inhibitor-class maintenance is likely to help after the next response.
If that testing was never done, or was done on blood alone and never on the tumour, it is worth revisiting at relapse rather than assuming the earlier answer still covers everything. CION provides BRCA and HRD testing and genetic counselling in-house, and the result can change the plan more than a month either side of the interval does.
Every band in the table above was derived by following large groups of women and reporting how the group behaved on average. Within any band individual outcomes vary enormously — some women with a short interval do well for a long time, and some with a long interval progress quickly.
Treat the interval the way your oncologist does: a strong hint about which treatment to reach for, and a weak one about anything else. It is not the number to go home and search survival figures against.
A logical-sounding idea was tested properly. In women in the six-to-twelve month band, platinum was deliberately delayed by giving a non-platinum drug first, so that the interval would be longer when platinum was eventually re-used. The MITO-8 trial randomised exactly that question, and manufacturing a longer gap did not improve outcomes.
The lesson is what the interval really is: a marker of how the cancer has behaved, not a lever you can pull. Lengthening the number on paper does not change the biology it was reporting. Source: Pignata S et al., MITO-8, Journal of Clinical Oncology (2017).
Bring the date of your last chemotherapy, your CA-125 trend and the most recent scan report. One 45-minute consultation is usually enough to work out your interval, what it changes, and what the reasonable options are from here.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed, and no cost for the first consultation. Bring your dates and reports — we will tell you plainly what the interval changes and what it does not.
You can do most of this yourself before the appointment. It makes the consultation considerably more useful, and it settles questions that a whole visit otherwise cannot.
It will be in the chemotherapy record or the discharge summary from the last cycle. Use the date the cycle was actually given, not the date it was planned, and not the date the whole course was scheduled to end. If a final cycle was cancelled because of side effects, the last one you received is the one that counts.
Usually the CT scan that showed disease again. Sometimes it is the date a confirmed CA-125 rise was acted on, particularly if symptoms had already begun. Bring the report itself rather than a remembered date — a few weeks matters most in the six-to-twelve month zone.
That figure is your interval. Do not add the months of maintenance therapy on top, and do not subtract weeks because you felt unwell earlier. If you did have maintenance therapy, write down both numbers: the platinum-free interval, and the treatment-free interval from your last dose of anything.
Histology and grade, BRCA and HRD status, any nerve damage or hearing change left from earlier chemotherapy, any previous allergic-type reaction to platinum, kidney and marrow function, and how you actually feel. Each of these can outweigh a month either way on the calendar.
Cure, control, or comfort — these lead to different choices, and the honest answer changes with the interval. Asking directly is not pessimism. It is the question that makes the rest of the plan make sense, and every oncologist should answer it plainly.
At CION every relapse plan is reviewed by a multidisciplinary group — medical oncology, imaging and pathology — rather than decided by one doctor in one clinic. A second opinion at this point is reasonable and expected, and it is free at CION.
Bring the chemotherapy record itself if you have it. One documented date does more for the next decision than an hour of discussion without it.
A relapse consultation is where a rushed appointment does the most damage. There are usually several defensible options, they differ in side effects as much as in effect, and choosing between them depends on facts about you that take time to draw out. Your first consultation at CION is free and runs to about 45 minutes, and second opinions on a relapse plan are welcome — bring your dates, scans and pathology.
Medical oncology is delivered in-house. Chemotherapy for relapse, maintenance therapy and follow-up run across 35+ centres in Telangana and Andhra Pradesh, so treatment can usually be given near where you live rather than requiring a trip to one city hospital every cycle. BRCA and HRD testing and genetic counselling are provided in-house too, along with nutrition and survivorship support. Every relapse plan is discussed at a tumour board.
Where surgery enters the conversation — secondary cytoreduction for a long interval and limited, well-defined disease — it is performed by specialist gynaecologic-oncology surgeons at partner centres and may be billed there. HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated the same way. We would rather say that plainly at the first visit than let you discover it halfway through a plan.
Free, unhurried and with a specialist. Long enough to go through your chemotherapy dates, scans and pathology properly, instead of accepting a category you were handed elsewhere.
Relapse plans are reviewed by medical oncology, imaging and pathology together. Grey-zone intervals in particular benefit from more than one opinion in the room.
BRCA and HRD testing and genetic counselling in-house, revisited at relapse where the earlier work-up was incomplete, because the result shapes maintenance therapy.
Chemotherapy and follow-up delivered close to home across Telangana and Andhra Pradesh, which matters more at relapse than it did the first time round.
Search for survival by platinum-free interval and you will find figures. They are real numbers from real studies, and they still will not be about you. They come from trial populations selected to be fit enough to enrol, they average across substages and across tumour subtypes that behave very differently, and many describe an era before routine BRCA and HRD testing and before maintenance therapy was standard. They also mix women whose first surgery removed all visible disease with women whose surgery could not.
That is not a reason to distrust your oncologist's judgement. It is a reason to ask about your own situation rather than a published band. The useful questions are what the aim of this next line is, what a response would look like, when it will be reassessed, and what the plan is if it does not work — not what proportion of a study population was alive at a given point.
CION publishes its own one-year survival alongside the national figure so the comparison is visible rather than implied. For ovarian cancer, 81.0% of CION patients are alive at one year, against a national figure of 73.7%. That is a one-year figure across the whole treated population — not a cure rate, and not a prediction for any individual.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
Neither figure is a cure rate, and neither describes a relapse. Your own outlook depends on stage, subtype, how the disease has behaved so far, and your general health.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own prognosis with your treating oncologist.
It is the length of time between the last dose of platinum-based chemotherapy you received and the date your ovarian cancer was documented to have come back or started growing again. It is often abbreviated to PFI. Nothing else goes into the calculation — not your stage, not your age, not your CA-125 level. It is used because, across decades of trials, it has been the single best predictor of whether platinum-based chemotherapy will produce another good response. A longer interval predicts a better chance of response, which is why platinum is usually offered again. A short interval points towards a different class of drug instead.
It starts on the day of your last dose of platinum-based chemotherapy, and it stops on the day relapse was documented. Surgery and the date of your original diagnosis play no part in it. If your last cycle was given in March and a scan in December showed disease again, the interval is roughly nine months, whatever happened in between. The stopping date is usually the scan, because that is the point at which relapse is confirmed rather than suspected. This is also why the number can feel shorter than your own experience of it — symptoms often begin weeks before the scan that finally documents them.
Conventionally, relapse within six months of the last platinum dose is called platinum-resistant, relapse after twelve months is called platinum-sensitive, and the six-to-twelve month band is described as partially platinum-sensitive. Disease that grows during treatment is called platinum-refractory. In practice the difference is a prediction about re-treatment, not two different cancers. The 5th Ovarian Cancer Consensus Conference recommended retiring the strict binary in 2015, because the six-month line was chosen to make trials comparable rather than drawn by biology. Your oncologist will still use the words, but the plan should be built from your whole picture, not from which side of a date you fall.
It does not stop the platinum-free clock, because that clock tracks platinum only. But it does matter, which is why the treatment-free interval exists alongside it. If you completed chemotherapy, stayed on PARP-inhibitor-class maintenance therapy for a year, and relapsed a month after stopping, your platinum-free interval is over twelve months while your treatment-free interval is only weeks. Those two numbers point towards different plans, so it is worth asking which one is being used about you. Make sure both dates are recorded in your notes: the last platinum dose, and the last dose of any treatment at all.
Neither label fits you well, and that is the honest answer rather than an evasive one. Six to twelve months is the partially platinum-sensitive band, and it is where oncologists genuinely disagree. Platinum may be re-used, often in combination, or a non-platinum option may be preferred — both are defensible. What tips the decision is everything sitting beside the interval: how you tolerated platinum before, whether nerve damage or hearing change persists, whether you had an allergic-type reaction, your BRCA and HRD status, how quickly the disease is moving, and what you want from the next few months. This is exactly the situation where a tumour board discussion, and a second opinion, earn their place.
It was a reasonable idea, and it was tested properly. The MITO-8 trial took women in the six-to-twelve month band and compared giving platinum-based chemotherapy at relapse against deliberately delaying it with a non-platinum drug first, so that the interval would be longer when platinum was eventually re-used. Manufacturing a longer gap did not improve outcomes. The result is a useful reminder of what the interval actually is: a marker of how the cancer has behaved, not a lever you can pull to change that behaviour. Decisions at relapse should be made on the merits of each option, not on stretching a number.
The first consultation is free and runs to about 45 minutes, and second opinions on a relapse plan are welcome. CION delivers medical oncology in-house: chemotherapy for recurrent disease, maintenance therapy, BRCA and HRD testing, genetic counselling, nutrition support and follow-up, across more than 35 centres in Telangana and Andhra Pradesh. Every relapse plan is reviewed at a tumour board rather than decided by a single doctor. Surgery at relapse, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist gynaecologic-oncology partner centres and may be billed there — we say so upfront rather than leaving it to be discovered later. Bring your chemotherapy dates, recent scans and pathology to the first visit.